Charles River Laboratories (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -15,562 | -14,802 | -142,163 | 134,127 | 78,571 |
| Depreciation Amortization | 134,441 | 67,151 | 568,312 | 325,035 | 239,871 |
| Income taxes - deferred | 12,077 | -29,417 | -75,292 | -15,122 | -41,030 |
| Accounts receivable | -87,135 | -65,319 | 35,737 | 8,106 | -18,490 |
| Accounts payable and accrued liabilities | 21,276 | 20,455 | 2,869 | 40,747 | 16,241 |
| Other Working Capital | -106,255 | -106,079 | 14,081 | 7,309 | 12,454 |
| Other Operating Activity | 261,960 | 169,088 | 334,102 | 89,924 | 88,683 |
| Operating Cash Flow | $220,802 | $41,077 | $737,646 | $590,126 | $376,300 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -11,805 | -8,492 | -20,076 | -12,544 | -8,090 |
| PPE Investments | -87,013 | -55,908 | -219,152 | -130,202 | -94,622 |
| Net Acquisitions | -290,691 | -344,910 | 17,441 | 17,441 | 17,441 |
| Sale Of Investment | 11,059 | 2,922 | 9,102 | 5,637 | 2,106 |
| Other Investing Activity | -1,298 | -1,457 | 3,364 | 3,154 | 347 |
| Investing Cash Flow | $-379,748 | $-407,845 | $-209,321 | $-116,514 | $-82,818 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 1,265,258 | 912,462 | 1,227,534 | 1,070,861 | 963,363 |
| Debt Repayment | -745,927 | -355,676 | -1,349,317 | -1,141,500 | -887,706 |
| Common Stock Issued | 1,620 | 1,223 | 714 | 3 | 1 |
| Common Stock Repurchased | -323,881 | -208,285 | -360,673 | -360,577 | -360,484 |
| Other Financing Activity | -14,007 | -2,000 | -54,984 | -53,649 | -47,420 |
| Financing Cash Flow | $183,063 | $347,724 | $-536,726 | $-484,862 | $-332,246 |
| Exchange Rate Effect | 467 | 1,248 | 18,828 | 14,900 | 17,934 |
| Beginning Cash Position | 215,997 | 215,997 | 205,570 | 205,570 | 205,570 |
| End Cash Position | 240,581 | 198,201 | 215,997 | 209,220 | 184,740 |
| Net Cash Flow | $24,584 | $-17,796 | $10,427 | $3,650 | $-20,830 |
| Free Cash Flow | |||||
| Operating Cash Flow | 220,802 | 41,077 | 737,646 | 590,126 | 376,300 |
| Capital Expenditure | -87,013 | -55,908 | -219,152 | -130,202 | -94,622 |
| Free Cash Flow | 133,789 | -14,831 | 518,494 | 459,924 | 281,678 |